Literature DB >> 11389096

Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance.

P D Cole1, B A Kamen, R Gorlick, D Banerjee, A K Smith, E Magill, J R Bertino.   

Abstract

Intracellular metabolism of methotrexate (MTX) to MTX-polyglutamates (MTXPG) is one determinant of cytotoxicity. Steady-state accumulation of MTXPG seems to depend on the activity of two enzymes: folylpolyglutamate synthetase (FPGS), which adds glutamate residues, and gamma-glutamyl hydrolase (GGH), which removes them. Overexpression of GGH would be expected to decrease intracellular MTXPG, thereby increasing efflux of MTX and decreasing cytotoxicity. Increased expression of GGH has been shown to be associated with resistance to MTX in human sarcoma cell lines and a rat hepatoma cell line. To clarify the specific role of GGH in determining MTX sensitivity, we investigated the phenotype produced by forced GGH overexpression in two cell types. Furthermore, because MTX and folic acid share metabolic pathways, we measured the effects of GGH overexpression on folic acid metabolism. The full-length cDNA for GGH, subcloned into a constitutive expression vector, was transfected into a human fibrosarcoma (HT-1080) and a human breast carcinoma (MCF-7) cell line. Compared with the clones containing an empty vector, the GGH-overexpressing cells express 15- to 30-fold more GGH mRNA, more GGH protein, and 15- to 90-fold more GGH enzyme activity. GGH overexpression altered MTX accumulation and metabolism to long-chain polyglutamates. In contrast to expectations, however, GGH overexpression did not confer resistance to short MTX exposures in either cell line. Changes in MTX metabolism were found to be balanced by alterations in accumulation and metabolism of folic acid. The ratio of MTX:folate accumulation may be a better predictor of MTX cytotoxicity than the accumulation of either alone. We conclude that, at least for these two cell lines, GGH overexpression alone is insufficient to produce clinical resistance to MTX.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389096

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.

Authors:  Bernd Kubista; Florian Klinglmueller; Martin Bilban; Martin Pfeiffer; Richard Lass; Alexander Giurea; Phillipp T Funovics; Cyril Toma; Martin Dominkus; Rainer Kotz; Theresia Thalhammer; Klemens Trieb; Teresa Zettl; Christian F Singer
Journal:  Int Orthop       Date:  2010-03-26       Impact factor: 3.075

2.  The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis.

Authors:  Ilan Ifergan; Gerrit Jansen; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

3.  Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy.

Authors:  Courtney Pollard; Matt Nitz; Alex Baras; Paul Williams; Christopher Moskaluk; Dan Theodorescu
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

4.  Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.

Authors:  K-J Sohn; F Smirnakis; D N Moskovitz; P Novakovic; Z Yates; M Lucock; R Croxford; Y-I Kim
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

5.  High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.

Authors:  Nathaniel Melling; Masoud Rashed; Cornelia Schroeder; Claudia Hube-Magg; Martina Kluth; Dagmar Lang; Ronald Simon; Christina Möller-Koop; Stefan Steurer; Guido Sauter; Frank Jacobsen; Franziska Büscheck; Corinna Wittmer; Till Clauditz; Till Krech; Maria Christina Tsourlakis; Sarah Minner; Hartwig Huland; Markus Graefen; Lars Budäus; Imke Thederan; Georg Salomon; Thorsten Schlomm; Waldemar Wilczak
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

Review 6.  Leptomeningeal disease: current diagnostic and therapeutic strategies.

Authors:  Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci
Journal:  Oncotarget       Date:  2017-08-16

7.  Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers.

Authors:  Luigi Scotto; Cristina Kinahan; Beatrice Casadei; Michael Mangone; Eugene Douglass; Vundavalli V Murty; Enrica Marchi; Helen Ma; Changchun George; Francesca Montanari; Andrea Califano; Owen A O'Connor
Journal:  Genes Chromosomes Cancer       Date:  2020-07-30       Impact factor: 5.006

8.  γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate.

Authors:  S-E Kim; P D Cole; R C Cho; A Ly; L Ishiguro; K-J Sohn; R Croxford; B A Kamen; Y-I Kim
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

9.  A genome scale overexpression screen to reveal drug activity in human cells.

Authors:  Anthony Arnoldo; Saranya Kittanakom; Lawrence E Heisler; Anthony B Mak; Andrey I Shukalyuk; Dax Torti; Jason Moffat; Guri Giaever; Corey Nislow
Journal:  Genome Med       Date:  2014-04-29       Impact factor: 11.117

10.  Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.

Authors:  Marta Hegyi; Adam Arany; Agnes F Semsei; Katalin Csordas; Oliver Eipel; Andras Gezsi; Nora Kutszegi; Monika Csoka; Judit Muller; Daniel J Erdelyi; Peter Antal; Csaba Szalai; Gabor T Kovacs
Journal:  Oncotarget       Date:  2017-02-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.